[{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chlorite","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neuvivo \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for SODIUM CHLORITE

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : NP001 is an investigational product (sodium chlorite), which is being investigated in the late-stage clinical trial for the treatment of amyotrophic lateral sclerosis.

                          Brand Name : NP001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 07, 2024

                          Lead Product(s) : Chlorite

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank